Default company panoramic image

Rotalactis s.r.l.

A proprietary peptide, derived from donkey's milk Lactadherin, for a natural vaccine-like prevention and treatment of Rotavirus infections

  • Stage Concept Only
  • Industry Biotechnology
  • Location Turin, Piedmont, Italy
  • Currency EUR
  • Founded December 2008
  • Employees 1
  • Website

Company Summary

Established in December 2008 in the BioIndustry Park (Ivrea, Italy) by researchers and academics of the National Research Council and of the University of Torino, it belongs to the porfolio of Eporgen and operates in the area of nutraceuticals. Is developing Rotalactine®, a novel, proprietary, dietary ingredient/supplement derived from equine milk Lactadherin for the prevention and treatment of neonatal infections by rotavirus.


  • Default avatar
    Enrico Bertino

    Associated professor of Neonatology at the University of Torino, Director of the Neonatal Intensive Care Unit c/o S.Anna Hospital, Torino. Secretary of the Italian Society of Human Milk Banks. He has published more than 190 articles on international journals. Co-Founder of Rotalactis.

  • Default avatar
    Claudio Fabris

    Full professor of Neonatology at the University of Torino. Past President of the Italian Society of Neonatology. Co-Founder of Rotalactis.

  • Default avatar
    David Lembo

    Associated Professor of Microbiology and Clinical Microbiology and Head of the Laboratory of Molecular Virology at the University of Turin. Author or co-author of more than 50 publications in peer-reviewed international journals and inventor of several patents in the field of antivirals and nanomedicine. Scientific consultant of several biotech companies and co-founder of RotaLactis.

  • Default avatar
    Amedeo Conti

    Research Director within the Institute of Alimentary Sciences of the National Research Council in Turin. Co-Founder, CEO and Chairman of the Board of Rotalactis.

Previous Investors

  • Default avatar
    Default avatar
    Piemonte High Technology